• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: ANRO )

3.970 +0.080 (+2.06%)
Streaming Delayed Price Updated: 9:32 AM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANRO

< Previous 1 2 Next >
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
October 27, 2024
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Nasdaq Down 2%; US Crude Stocks Increase
October 23, 2024
Via Benzinga
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
October 23, 2024
Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies. 
Via Benzinga
Gold Moves Lower; AT&T Earnings Top Views
October 23, 2024
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 23, 2024
Via Benzinga
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
October 23, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 23, 2024
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 23, 2024
Via Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
October 23, 2024
Via Benzinga
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm
October 22, 2024
From The Schall Law Firm
Via Business Wire
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
October 22, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
September 04, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
September 03, 2024
From Alto Neuroscience, Inc.
Via Business Wire
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024
August 13, 2024
ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
July 25, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
July 16, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
June 20, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
June 18, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On
June 10, 2024
Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors. 
Via InvestorPlace
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
May 21, 2024
From Alto Neuroscience, Inc.
Via Business Wire
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024
May 14, 2024
ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 14, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
May 09, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
April 23, 2024
Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia. 
Via Benzinga
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
April 23, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
April 03, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
March 21, 2024
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
March 11, 2024
From Alto Neuroscience, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap